Tarsus joins Stargardt race to market with $800m Alkeus takeover
Alongside Alkeus, several companies like Belite Bio, Ocugen and Nanoscope are aiming to secure a place on the Stargardt market…
Featured s
Context drops bispecific T-cell engager on cost-cutting initiative
The biotech will now focus on the two other BiTEs in its pipeline, CTIM-76 and CT-202.
All Articles
Tarsus joins Stargardt race to market with $800m Alkeus takeover
Alongside Alkeus, several companies like Belite Bio, Ocugen and Nanoscope are aiming to secure a place on the Stargardt market…
Context drops bispecific T-cell engager on cost-cutting initiative
The biotech will now focus on the two other BiTEs in its pipeline, CTIM-76 and CT-202.
Moderna mRNA flu shot wins FDA approval but awaits CDC recommendations
The approval means mFlusiva becomes the first mRNA-based vaccine to be authorised on the US market for flu prevention.
Evotec and Odyssey collaborate on AI-enabled R&D
The partnership intends to leverage complementary scientific strengths to boost early-stage research and produce new medicines.
Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments
The partnership gives Ono the exclusive option to license worldwide rights to develop the therapeutic programmes.
Takeda nets first-in-class advantage on narcolepsy drug’s FDA go-ahead
GlobalData analysts previously flagged Orzeyful’s approval as a key Q3 catalyst for the pharma industry due to the drug’s ‘transformative’…
Rethinking sterile product development for manufacturing success
How evolving development priorities are helping organisations build manufacturing knowledge from the earliest stages of development.
Eli Lilly raises 2026 outlook again as Q2 soars past estimates
Reporting 91% growth for Mounjaro, Lilly widened the gap to cardiometabolic rival Novo Nordisk.
Alteogen signs $365m Hybrozyme licensing deal with pharma company
Alteogen is set to receive an upfront payment and could earn additional amounts through development, regulatory, and sales milestone payments.
China-ready by design: Leveraging NMPA’s new 30‑working day IND pathway
China is becoming a global hub for oncology trials, offering access to a large and diverse patient population that can…